Nick Devoogdt

Nick Devoogdt (°1975) studied Molecular Biology at the Vrije Universiteit Brussel (VUB, Belgium) and received his MSc degree in 1997. He graduated as a PhD in Applied Biological Sciences in 2004, studying cancer genetics and tumor immunology. In 2004-2005 he was a visiting scientist at the National Cancer Institute in Bethesda, USA, studying ovarian cancer genetics and biomarkers, after which he returned to VUB in Belgium for additional postdoctoral training: in 2005-2006 in the field of cellular immunology and cancer genetics, in 2007 in antibody-engineering and from 2008 onwards in molecular imaging. In 2013 he became assistant professor (0.1ZAP) in the In vivo Cellular and Molecular Imaging laboratory (ICMI) and since 2016 tenure-track full professor and principal investigator. In 2023 he became the Head of the new MITH Large Research Group. His research aims to develop novel applications in molecular and nuclear imaging and targeted therapies. His current focus is on the camelid single-domain antibody-technology as targeting vehicles in disease areas ranging from oncology and immunology to cardiovascular research, inflammation and diabetes. More in particular, his research is focused on the generation of new probes for their application (nuclear or other types of imaging and therapy) in small animal models of disease, and translate proficient compounds to the clinic.